The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 01, 2018

Filed:

Jul. 21, 2014
Applicant:

Spriaso Llc, Salt Lake City, UT (US);

Inventors:

William I. Higuchi, Salt Lake City, UT (US);

Firoozeh Aminian Patel, Salt Lake City, UT (US);

Assignee:

SPRIASO LLC, Salt Lake City, UT (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/381 (2006.01); A61K 31/135 (2006.01); A61K 45/06 (2006.01); C07D 333/20 (2006.01); A61K 31/245 (2006.01); A61K 31/24 (2006.01); C07C 215/64 (2006.01); C07C 219/26 (2006.01);
U.S. Cl.
CPC ...
A61K 31/381 (2013.01); A61K 31/135 (2013.01); A61K 31/24 (2013.01); A61K 31/245 (2013.01); A61K 45/06 (2013.01); C07D 333/20 (2013.01); C07C 215/64 (2013.01); C07C 219/26 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01);
Abstract

Described are compositions that may be orally administered that comprise a bioreversible derivative of hydroxy N-substituted-2-aminotetralin or an enantiomer or salt or prodrug thereof, and a pharmaceutically acceptable carrier suitable for oral administration in the amount present, wherein the composition is orally bioavailable when administered to a subject. The bioreversible derivative has an intrinsic lipophilicity C log P value of about 7 to about 11.5. A method comprises oral administering such composition to a human subject in need of hydroxy N-substituted-2-aminotetralin therapy.


Find Patent Forward Citations

Loading…